Erbitux Fails First-Line Pancreatic Cancer Trial, But ImClone/Bristol Will Move Program Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Cetuximab is currently being evaluated in nine other Phase I and II trials for pancreatic cancer, which will continue.